Follow Us:
OB/GYNs, Primary Care Physicians, Nurse Practitioners, Physician's Assistants, Endocrinologists
Women's Health, Vulvovaginal atrophy, Genitourinary Syndrome of Menopause
Sheryl A. Kingsberg is a clinical psychologist and Professor in the Department of Reproductive Biology at Case Western Reserve University School of Medicine, and is the chief of the division of behavioral medicine in the department of OB/GYN at Case Medical Center, University Hospitals of Cleveland.
Dr. Goldstein has been involved with sexual dysfunction research since the late 1970's. His interests include penile microvascular bypass surgery, surgery for dyspareunia, sexual health management post cancer treatment, physiologic investigation of sexual function in men and women, and diagnosis and treatment of sexual dysfunction in men and women. Dr. Goldstein has authored more than 350 publications in the field of sexual dysfunction, and edited books on erectile dysfunction and on women’s sexual health. He is also Editor-in-Chief of Sexual Medicine Reviews and past Editor-in-Chief of The Journal of Sexual Medicine, official journals of the International Society for Sexual Medicine, its regional affiliate societies, and the International Society for the Study of Women’s Sexual Health. Dr. Goldstein is Director of Sexual Medicine at Alvarado Hospital, Clinical Professor of Surgery at University of California at San Diego and Director of San Diego Sexual Medicine where he maintains his clinical practice.| 1. | Express the physical, psychological, and interpersonal burden resulting from the symptoms of Genitourinary Syndrome of Menopause (GSM), Vulvovaginal atrophy (VVA), dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) after menopause | 2. | Explain the changes in genitourinary morphology that occur as a result of menopause |
| 3. | Review the benefits and limitations of traditional treatments for dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) | 4. | Explain the etiology of/and treatment options for Hypoactive Sexual Desire Disorder (HSDD) |
| 1. | Express the physical, psychological, and interpersonal burden resulting from the symptoms of Genitourinary Syndrome of Menopause (GSM), Vulvovaginal atrophy (VVA), dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) after menopause |
| 2. | Explain the changes in genitourinary morphology that occur as a result of menopause |
| 3. | Review the benefits and limitations of traditional treatments for dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) |
| 4. | Explain the etiology of/and treatment options for Hypoactive Sexual Desire Disorder (HSDD) |
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |